Product Overview

Innovative Therapies for Antibiotic Resistant Infections

Aridis Pipeline

 

Our product candidates are highly differentiated from all antibiotics in mechanism of action, durability of action, and safety profile. Our product pipeline targets infectious diseases that have a significant impact on life expectancy and address acute medical needs including:

 

Out-licensed Products

Product Target Preclinical IND Phase 1 Phase 2 Phase 3
AR-105 mAb Gram (-) Bacteria
P. aeruginosa -toxin
HAP/VAP caused by P. aeruginosa70%
 
AR-201 mAb RSV Virus
F-protein
RSV17%
 
Product/Target Indication Phase
AR-105 mAb / Gram (-) Bacteria P. aeruginosa Alginate HAP/VAP caused by P. aeruginosa Phase 2
AR-201 mAb / RSV Virus F-protein RSV Preclinical

Fully human monoclonal antibodies (mAb) directed against infectious disease targets is a growing area of drug development interests. Anti-infective mAbs is a new class of anti-infective that has the potential to be standard of care treatments due to their strong safety profile in humans, remarkably long plasma half-life and low risk of drug resistance.

Aridis has developed a suite of human mAbs as anti-infective drugs targeting key human pathogens, including S. aureus (MRSA & MSSA), P. aeruginosa, A. baumannii bacteria and respiratory syncytial virus. Complementing these mAbs is a broad spectrum anti-infective candidate based on the unique iron analog properties of gallium (Panaecin®).